BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

(MENAFN- GlobeNewsWire - Nasdaq) Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

today announced an upcoming presentation of preclinical data on the development of IL1RAP-targeting antibody-drug conjugates (ADCs). ADCs are already making a difference to cancer patients' lives ...